This site is intended for healthcare professionals
Diagnosis and management of primary hyperoxaluria type 1
Declaration of sponsorship Alnylam Pharmaceuticals

PH1 diagnosis

Declaration of sponsorship Alnylam Pharmaceuticals
Read time: 5 mins
Last updated:6th Apr 2021
Published:6th Apr 2021

Would recurrent urolithiasis, nephrocalcinosis or unexplained end-stage kidney disease (ESKD) make you think of primary hyperoxaluria type 1 (PH1)?

Recognising the signs is the first step in managing this progressive disease.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Developed by EPG Health for Medthority.com, with all content provided by Alnylam Pharmaceuticals. Learning Zone sponsored and funded by Alnylam Pharmaceuticals. Please note that this material is intended for healthcare professionals only. 

Date of preparation: March 2021 │ OXL-CEMEA-00010

© Copyright 2021